FDA Clears Telomir-Zn IND for Triple-Negative Breast Cancer, Paving Way for Phase 1/2 Trial
TELO sits 42% above its 52-week low of $1.05 on elevated volume (1.9× avg).
Summary
Telomir Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for Telomir-Zn, its lead candidate for advanced or metastatic triple-negative breast cancer (TNBC). This critical regulatory milestone allows the company to initiate a first-in-human Phase 1/2 clinical trial in the first half of 2026, a significant step for a clinical-stage biotech. This positive development provides a crucial catalyst for the company, especially in light of its previously disclosed financial challenges and going concern warning from its last 10-K. While the company recently completed an acquisition to consolidate IP, this IND clearance directly advances its pipeline. Traders will now focus on the initiation of the Phase 1/2 trial and subsequent updates on patient enrollment and preliminary data.
At the time of this announcement, TELO was trading at $1.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.9M. The 52-week trading range was $1.05 to $3.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.